Intellia Therapeutics (NTLA) Change in Receivables (2016 - 2025)
Historic Change in Receivables for Intellia Therapeutics (NTLA) over the last 10 years, with Q3 2025 value amounting to -$303000.0.
- Intellia Therapeutics' Change in Receivables rose 9127.81% to -$303000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 706.73%. This contributed to the annual value of -$27.9 million for FY2024, which is 18547.17% down from last year.
- As of Q3 2025, Intellia Therapeutics' Change in Receivables stood at -$303000.0, which was up 9127.81% from $849000.0 recorded in Q2 2025.
- In the past 5 years, Intellia Therapeutics' Change in Receivables ranged from a high of $30.0 million in Q4 2023 and a low of -$24.1 million during Q2 2024
- Over the past 5 years, Intellia Therapeutics' median Change in Receivables value was $151000.0 (recorded in 2023), while the average stood at $469473.7.
- Its Change in Receivables has fluctuated over the past 5 years, first soared by 1185098.04% in 2023, then plummeted by 1605960.26% in 2024.
- Intellia Therapeutics' Change in Receivables (Quarter) stood at -$460000.0 in 2021, then surged by 44.57% to -$255000.0 in 2022, then soared by 11850.98% to $30.0 million in 2023, then plummeted by 101.12% to -$337000.0 in 2024, then increased by 10.09% to -$303000.0 in 2025.
- Its Change in Receivables stands at -$303000.0 for Q3 2025, versus $849000.0 for Q2 2025 and $2.0 million for Q1 2025.